NBIX · Intrinsic value
Is Neurocrine Biosciences, Inc. (NBIX) overvalued or undervalued?
Neurocrine Biosciences, Inc. (NBIX) trades at the delayed market price of $135.71 a share. That price already implies revenue growth of 14.7% a year for 5 years. TickerWorth's fair value is $164.85 a share (priced within our range of $100.19 – $205.79). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
Is NBIX fairly valued?
- Fair value
- $164.85
- Market price
- $135.71
- Upside to fair value
- +21.5%
- Verdict
- Priced within our range of $100.19 – $205.79
Reverse DCF: Today's price implies revenue growth of 14.7% a year for 5 years; our model assumes 16.6% a year on average over the same horizon.
What is NBIX's TickerWorth Score?
Scores higher than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: a profitable, high-quality business. Its weakest: recent price trend has been weak.
- Value · 62 of 100
Cheaper than 62% of Healthcare companies in US
- Price vs worth · 67 of 100
- Quality · 73 of 100
More profitable than 73% of Healthcare companies in US
- Financial health · 61 of 100
Financially stronger than 61% of Healthcare companies in US
- Growth · 73 of 100
Growing faster than 73% of Healthcare companies in US
- Momentum · 35 of 100
Outperformed 35% of Healthcare companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
NBIX DCF valuation, input by input
TickerWorth's fair value for Neurocrine Biosciences, Inc. (NBIX) is $164.85 a share, against the delayed market price of $135.71 (priced within our range of $100.19 – $205.79). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values NBIX at about $161.75 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts Neurocrine Biosciences, Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 7.1%, with a long-run terminal growth rate of 2.5%. About 81% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 14.7% annual revenue growth for NBIX. Our base case instead compounds to about 16.6% a year over the same forecast, so the market's implied growth is broadly in line with our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, NBIX's modeled DCF value ranges from about $107.96 to $340.05 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Neurocrine Biosciences, Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of NBIX's intrinsic value. Figures update as new filings and prices come in.
Every input behind NBIX's DCF
| Input | Value |
|---|---|
| Base-year revenueNEUROCRINE BIOSCIENCES INC FY2025 10-K (accession 0000914475-26-000007): us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, FY2025 full year. | $2,860,500,000 |
| Base EBIT marginNEUROCRINE BIOSCIENCES INC FY2025 10-K (accession 0000914475-26-000007): us-gaap:OperatingIncomeLoss 619,100,000 / revenue 2,860,500,000 = 21.64%, FY2025. | 21.6% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 30% → 24% → 17% → 10% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.3% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.40 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesNEUROCRINE BIOSCIENCES INC FY2025 10-K (accession 0000914475-26-000007): WeightedAverageNumberOfDilutedSharesOutstanding = 102,500,000 shares, FY2025. | 102M |
| Market priceBackup price feed · as of 2026-10-19 13:20 UTC | $135.71 |
Change NBIX's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Neurocrine Biosciences, Inc. do?
What does it do?
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in United States. The company employs roughly 2,500 people.
How does it make money?
The business turns $3.4B in annual revenue into profit. Out of every $100 of sales, about $22 is left as operating profit (operating margin of 22.2%), after a 64% gross margin on the products/services it sells. After all costs, taxes and interest, 20.9% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.1× equity), comfortably covers its short-term bills (1.9× current ratio), and is currently profitable.
Who at NBIX filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Boyer David W. | Chief Corp. Affairs Officer | Open-market sale | $130,050.56 | Form 4 for Boyer David W. (opens sec.gov in a new tab) | |
| ABERNETHY MATT | Chief Financial Officer | Open-market sale | $363,284.81 | Form 4 for ABERNETHY MATT (opens sec.gov in a new tab) | |
| Onyia Jude | Chief Scientific Officer | Grant / award | — | Form 4 for Onyia Jude (opens sec.gov in a new tab) | |
| Onyia Jude | Chief Scientific Officer | Shares withheld (tax) | $302,441.92 | Form 4 for Onyia Jude (opens sec.gov in a new tab) | |
| Lippoldt Darin | Chief Legal Officer | Grant / award | — | Form 4 for Lippoldt Darin (opens sec.gov in a new tab) | |
| Lippoldt Darin | Chief Legal Officer | Shares withheld (tax) | $377,896.18 | Form 4 for Lippoldt Darin (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is NBIX's intrinsic value?
TickerWorth's blended fair value for Neurocrine Biosciences, Inc. (NBIX) is $164.85 per share, versus a market price of $135.71 (priced within our range of $100.19 – $205.79).
Is NBIX overvalued or undervalued?
Priced within our range of $100.19 – $205.79 at $135.71. We don't call NBIX overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for NBIX?
A WACC of 7.1% and a terminal growth rate of 2.5%.
Is Neurocrine Biosciences stock undervalued?
TickerWorth's fair value for Neurocrine Biosciences, Inc. (NBIX) is $164.85 against a market price of $135.71. Our read: Priced within our range of $100.19 – $205.79. This is a model estimate, not investment advice.
Neurocrine Biosciences (NBIX) DCF valuation and fair value
Our fair value for Neurocrine Biosciences, Inc. (NBIX) is $164.85, built on a 7.1% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Neurocrine Biosciences stock?
Today's price implies revenue growth of 14.7% a year for 5 years; our model assumes 16.6% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $135.71. A model estimate, not investment advice.
Neurocrine Biosciences (NBIX) insider trading
The most recent insider filing (SEC Form 4) for Neurocrine Biosciences, Inc. (NBIX): Boyer David W., Chief Corp. Affairs Officer, open-market sale on 2026-09-14. The latest filings are listed on this page. A disclosure, not a signal to trade.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.